Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b study of FIN-211 in children with autism spectrum disorder (ASD) and gastrointestinal symptoms

X
Trial Profile

A Phase 1b study of FIN-211 in children with autism spectrum disorder (ASD) and gastrointestinal symptoms

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FIN-211 (Primary)
  • Indications Gastrointestinal disorders; Pervasive child development disorders
  • Focus Adverse reactions
  • Acronyms AUSPIRE
  • Sponsors Finch Therapeutics Group
  • Most Recent Events

    • 01 Sep 2022 According to a Finch Therapeutics media release, the company have decided to suspend efforts to initiate this phase 1 trial while it will explore opportunities to leverage clinical data from ongoing third-party studies to inform our autism program strategy going forward.
    • 16 May 2022 According to a Finch Therapeutics media release, company anticipates submitting the IND for FIN-211 in Q4 2022.
    • 31 Mar 2022 According to a Finch Therapeutics Group media release, this trial will be delayed in connection with the clinical hold related to the IND for CP101.Finch is evaluating the extent of the expected delay to the timing of AUSPIRE and, based on manufacturing timelines, expects at least a one quarter delay.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top